Answers are grounded in this paper and cite their sources.
This single-blind, multicenter, placebo controlled, parallel study demonstrates that intralesional interferon alpha-2b at a dose of 5 x 10(6) units biweekly for 12 weeks is effective and safe as minimally invasive therapy for Peyronie's disease.
No takes yet. Share an insight, caveat, or question.
Hellstrom et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: